Literature DB >> 9808852

Low-dose low-molecular-weight heparin is anti-inflammatory during venous thrombosis.

L J Downing1, R M Strieter, A M Kadell, C A Wilke, L J Greenfield, T W Wakefield.   

Abstract

PURPOSE: Venous thrombosis results in a vein wall inflammatory response initiated by thrombus. Although anticoagulation with standard heparin (SH) and low-molecular-weight heparin (LMWH) is known to limit further thrombosis, their anti-inflammatory properties are poorly defined. The anti-inflammatory properties of these heparins were studied.
METHODS: Sprague-Dawley rats were divided into groups and underwent inferior vena caval (IVC) ligation just below the renal level producing IVC thrombosis. One hour before ligation, animals received subcutaneous SH or LMWH at either high or low dose; normal saline (NS) was used as control. Six hours after ligation, animals were killed, and the IVCs were analyzed for clot presence, vein wall morphometrics, and vein wall permeability (VP) to define injury.
RESULTS: Animals in both low-dose groups had no measurable anticoagulation, whereas those in both high-dose groups were adequately anticoagulated. There were statistically less IVC neutrophils for all groups compared with the control group, with low-dose LMWH showing the least cells (low-dose LMWH, 16 +/- 3; high-dose LMWH, 37 +/- 10; low-dose SH, 37 +/- 6; high-dose SH, 32 +/- 9; NS control, 63 +/- 2). Similar results were noted for total inflammatory cells. The lowest VP was noted for low-dose LMWH.
CONCLUSION: Although both SH and LMWH inhibited vein wall neutrophils and total inflammatory cells, low-dose LMWH was most effective limiting neutrophil extravasation and was the only intervention to decrease VP below control levels. This occurred without preventing thrombus formation or causing a state of anticoagulation. Low-dose LMWH possesses anti-inflammatory properties distinct from its anticoagulant properties.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9808852     DOI: 10.1016/s0741-5214(98)70060-6

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  21 in total

Review 1.  Medical Treatment for Postthrombotic Syndrome.

Authors:  Federico Silva Palacios; Suman Wasan Rathbun
Journal:  Semin Intervent Radiol       Date:  2017-03       Impact factor: 1.513

2.  A randomized trial of dalteparin compared with ibuprofen for the treatment of superficial thrombophlebitis.

Authors:  S W Rathbun; C E Aston; T L Whitsett
Journal:  J Thromb Haemost       Date:  2012-05       Impact factor: 5.824

3.  Vein wall remodeling after deep vein thrombosis: differential effects of low molecular weight heparin and doxycycline.

Authors:  Vikram Sood; Cathy Luke; Erin Miller; Mayo Mitsuya; Gilbert R Upchurch; Thomas W Wakefield; Dan D Myers; Peter K Henke
Journal:  Ann Vasc Surg       Date:  2010-02       Impact factor: 1.466

4.  Low-molecular-weight heparin modulates vein wall fibrotic response in a plasminogen activator inhibitor 1-dependent manner.

Authors:  Andrea T Obi; Jose A Diaz; Nicole L Ballard-Lipka; Karen J Roelofs; Diana M Farris; Daniel A Lawrence; Peter K Henke; Thomas W Wakefield
Journal:  J Vasc Surg Venous Lymphat Disord       Date:  2014-10-01

Review 5.  Neutrophil extracellular trap (NET) impact on deep vein thrombosis.

Authors:  Tobias A Fuchs; Alexander Brill; Denisa D Wagner
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-05-31       Impact factor: 8.311

Review 6.  Straight to the heart: Pleiotropic antiarrhythmic actions of oral anticoagulants.

Authors:  Anke C Fender; Reza Wakili; Dobromir Dobrev
Journal:  Pharmacol Res       Date:  2019-05-02       Impact factor: 7.658

7.  Vein wall re-endothelialization after deep vein thrombosis is improved with low-molecular-weight heparin.

Authors:  Daria K Moaveni; Erin M Lynch; Cathy Luke; Vikram Sood; Gilbert R Upchurch; Thomas W Wakefield; Peter K Henke
Journal:  J Vasc Surg       Date:  2008-03       Impact factor: 4.268

8.  Thrombus-targeted nanocarrier attenuates bleeding complications associated with conventional thrombolytic therapy.

Authors:  Shahriar Absar; Kamrun Nahar; Young Min Kwon; Fakhrul Ahsan
Journal:  Pharm Res       Date:  2013-03-07       Impact factor: 4.200

Review 9.  Prevention of the Post-Thrombotic Syndrome.

Authors:  Teresa L Carman
Journal:  Curr Treat Options Cardiovasc Med       Date:  2016-08

10.  The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial.

Authors:  Christina U Lorentz; Erik I Tucker; Norah G Verbout; Joseph J Shatzel; Sven R Olson; Brandon D Markway; Michael Wallisch; Martina Ralle; Monica T Hinds; Owen J T McCarty; David Gailani; Jeffrey I Weitz; András Gruber
Journal:  Blood       Date:  2021-12-02       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.